August 27, 2020 — Machine learning and model-based drug discovery is rapidly becoming the norm. Computational biology is now integrating ‘wet’ in vitro/in vivo and ‘dry’ in silico biology accelerating and saving time and resources, at least in the early stages of drug discovery. This MassBio panel discussion explored the new world of digital biology as a way to model potential drug effects more accurately and quickly.
Read more
August 13, 2020 — Cell therapy clinical trials typically generate a significant quantity and diversity of biologic data intended to characterize disease and patient biology, as well as data intended to demonstrate evidence of therapeutic mechanisms. QuartzBio’s Cliff Culver et al., explores the benefits of capturing and integrating molecular biomarker data within clinical trials to build foundations for data assets. Read the article in the latest issue of Applied Clinical Trials Magazine.
Click here to view the article
Read more
Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.
QUARTZBIO® and the PRECISION QUARTZBIO® logo are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved.
© 2024. All rights reserved.
Precision Medicine Group, LLC.
Privacy Policy | GDPR
Web Design and Development by RainCastle Communications.